PDCD1 and triple-negative breast carcinoma: For example, recent clinical trials of patients with metastatic triple-negative breast cancer found equivalent median progression-free survival (PFS) with anti-PD-1 monotherapy relative to historical chemotherapy controls, with only 19–21% patients showing overall response [4–6].